Table 2.
Number of drug resistance mutations (n pts) | Months on ART | Sex | VL at study enrollment (copies/mL) | CD4 at study enrollment (cells/mm3) | NNRTI | NRTI |
---|---|---|---|---|---|---|
≥5 (n=8 pts) | ||||||
| ||||||
1* | 48 | F | 3 010 | 524 | K101E+V108I+Y181C | D67N+K70R+M184V+K219E |
2** | 49 | F | 2 680 | 213 | K101H+K103N+V106M+G190A+F227L | D67N+M184V |
3*,^ | 41 | F | 4310 | 354 | K101E+V106M+G190A | D67N+M184V |
4 | 44 | F | 75 000 | 89 | K103N+P225H | D67N+K70R+M184V+T215F+K219E |
5* | 22 | F | 1850 | 342 | K103N+V108I | A62V+V75I+M184V |
6* | 45 | F | 773 | 384 | V106M+G190A | M41L+D67N+K70R+M184V |
7* | 44 | F | 2 530 | 199 | V106M+Y188LH | D67N+M184V+K219E |
8 | 45 | F | 18 200 | 496 | V106M+Y188L | M41L+D67N+K70R+M184V+T215Y |
| ||||||
4 (n=6 pts) | ||||||
| ||||||
9 | 15 | F | 16 900 | 160 | K101E+V108I+G190A | M184V |
10 | 45 | F | 11 000 | 464 | K101H+K103N+G190A | M184V |
11 | 46 | F | 3 000 | 354 | K103N+P225H | V75I+M184V |
12* | 37 | M | 49 900 | 16 | K103N+Y181C+P225H | M184I |
13^ | 47 | F | 54 700 | 419 | K103N+G190A+P225H | M184V |
14 | 47 | F | 9 670 | 377 | K103N+V106A+G190A | K65R |
| ||||||
3 (n=10 pts) | ||||||
| ||||||
15* | 48 | F | 18 300 | 331 | K101E+Y188L | M184I |
16 | 13 | F | 6 890 | 214 | K101E+V106M | M184V |
17 | 41 | F | 5 340 | 319 | K103N | D67N+M184V |
18* | 46 | F | 407 | 269 | K103N+P225H | M184V |
19 | 47 | F | 6 510 | 190 | K103N+V108I | M184V |
20* | 47 | F | 1 330 | 277 | K103N+V108I | M184V |
21 | 47 | M | 31 000 | 99 | K103N+V108I | M184V |
22** | 47 | F | 1 280 | 642 | K103N+V106M | M184V |
23* | 40 | F | 955 | 276 | V106M | A62V+M184V |
24 | 84 | F | 43 800 | 174 | V106M+Y188C | M184V |
| ||||||
2 (n=2 pts) | ||||||
| ||||||
25 | 43 | M | 430 | 151 | K103N | M184V |
26**,^ | 47 | F | 1 370 | 320 | K103N | M184V |
| ||||||
1 (n=5 pts) | ||||||
| ||||||
27** | 44 | M | 178 000 | 47 | K103N | --- |
28** | 46 | F | 56 500 | 187 | K103N | --- |
29** | 45 | F | 42 800 | 100 | K103N | --- |
30* | 45 | M | 1 130 | 439 | K103N | --- |
31^ | 46 | F | 43 900 | 193 | K103N | --- |
| ||||||
No major mutations (n=7 pts) | ||||||
| ||||||
32 | 46 | F | 552 | 369 | No major mutations | No major mutations |
33** | 41 | F | 882 000 | 90 | No major mutations | No major mutations |
34** | 47 | F | 1450 | 192 | No major mutations | No major mutations |
35*,^ | 43 | M | 83 000 | 103 | No major mutations | No major mutations |
36^ | 47 | F | 77 500 | 232 | No major mutations | No major mutations |
37**,^ | 43 | M | 312 000 | 203 | No major mutations | No major mutations |
38^ | 50 | M | 493 000 | 157 | No major mutations | No major mutations |
| ||||||
Not amplifiable (n=5 pts) | ||||||
| ||||||
39 | 44 | F | 463 | 357 | --- | --- |
40*,^ | 43 | F | 4 660 | 554 | --- | --- |
41**,^ | 41 | M | 1 060 | 430 | --- | --- |
42** | 13 | F | 557 | 445 | --- | --- |
43** | 55 | F | 66 800 | 379 | --- | --- |
Pts, patients; W, woman; M, man; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-NRTI, VL: virus load
Pts, patients; F, female; M, male; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-NRTI, VL: virus load
Persistent virologic ailure at follow-up
Re-suppressed at follow-up
Came late >7 days for the last drug-refill visit